SNDX-5613 - Syndax Pharma
SNDX-5613: "6 of 12 pts who achieved CR/CRh have a duration of response > 6 months"; Acute myeloid leukemia (Syndax) - Jan 20, 2022 - Corporate Presentation 
P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology
https://ir.syndax.com/static-files/ec1ddcca-2728-4880-ae53-9900a088c844
 
Jan 20, 2022
 
 
190c49f4-bb79-4f11-983a-2cef279375e5.png

b85de59c-a1c2-413b-b905-62bf792bb6ad.png

d8e3312a-9d32-458a-8754-a9870127d082.png